As the largest provider of bone marrow cell transplants in California, and the second largest in the nation, our institution has great expertise and an excellent record of safety in…
The proposed research will demonstrate both safety and efficacy of a heart-derived stem cell product in patients who have experienced a heart attack either recently or in the past by…
Therapeutic Candidate or Device Novel testing of a cell based therapy (Mesenchymal Stromal Cells) for respiratory failure from ARDS. Indication COVID-19 positive or negative ARDS patients Therapeutic Mechanism It will…
Therapeutic Candidate or Device Autologous CD34+ cells transduced ex vivo with the BCH_BB694 LCR(-HS4) bGp D12shmiR lentiviral vector Indication Sickle cell disease with severe phenotype. Therapeutic Mechanism Silencing of beta-sickle…
Expand capacities to deliver novel cell and gene therapy treatments to diverse communities across four California Counties (REAL: ORange, RivErside, San BernArdino, and Los Angeles). We will conduct regenerative medicine…
The CIRM Alpha Clinic will expand capacities and workforce expertise to accelerate development, clinical testing, and dissemination of novel cell and gene therapies for a broad range of conditions that…
The ASCC provides infrastructure and operational support across the Network to drive novel stem cell therapies from bench to bedside. The ASCC will engage underserved communities in California to increase…
1. Strengthen and expand collaborations with ASCC Network partners with lead offerings 2. Improve access to clinical trials for diverse populations 3. Expand regenerative medicine clinical trial portfolio in major…
The UC Davis Alpha Stem Cell Clinic has improved operations and streamlined processes for conducting stem cell and gene therapy clinical trials. The current proposal will accelerate and expand our…
City of Hope has long developed groundbreaking therapies, and building on that success we want to democratize cancer care by bringing therapies to patients rather than making them come to…
